SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the ...

A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and should even be effective against new strains ...

U.S. Antiviral Drugs Market to Surpass USD 27.07 Billion by 2032, Fueled by Chronic Infection Treatment Demand and Strong R&D Ecosystem.Austin, July 17, 2025 (GLOBE NEWSWIRE) -- Antiviral Drugs Market ...

A group of researchers says delayed treatment of a type of bird flu now spreading on dairy farms in the United States may ...

Company shares doubled on Phase 2 study results suggesting its drug could become an alternative to vaccines for flu prevention.

The first and most widely used single-dose antiviral flu pill is baloxavir marboxil, marketed as Xofluza and developed by the ...

Severe fever with thrombocytopenia syndrome (SFTS) was reported in Asia, with a fatality rate that can reach as high as 50%.

NanoViricides, Inc. (NYSE American: NNVC) , a clinical-stage developer of broad-spectrum antivirals using host-mimetic nanomedicine, announced promis ...

A new long-acting influenza drug by Cidara Therapeutics demonstrated up to 76% protection against symptomatic flu in a phase ...

Background The large-scale deployment of antiviral drugs from the Strategic National Stockpile during the 2009 H1N1 influenza response provides a unique opportunity to study local public health ...